ValuentumAd

Official PayPal Seal

Johnson & Johnson Faces Currency Headwinds But Its Stock Remains Undervalued

publication date: Jul 17, 2012
 | 
author/source: RJ Towner

Healthcare and consumer products giant Johnson & Johnson (click ticker for report: JNJ) reported second quarter earnings that were about in-line with expectations Tuesday morning. The firm posted adjusted earnings of $1.30 per share, a penny shy of expectations and down 2% on a year-over-year basis. Revenue was about $200 million lower than expected, but for a company that did $16.5 billion in revenue in the quarter, we think that difference is fairly immaterial.

When adjusting for currency effects, Johnson & Johnson’s international businesses performed fairly well, and in many respects, outperformed its US counterparts. The US consumer business’ revenue declined 1.9% from the same period a year ago, but internationally, it advanced 2% (net of currency effects). The firm’s pharmaceutical business performed well internationally thanks to the launch of several patent-protected drugs in Europe, increasing 15.5% year-over-year (excluding currency fluctuations). This compares to a decline of 4.5% in its US business. Medical device sales grew 2.9% in the US and advanced 3.8% on a constant currency basis internationally. We expect performance in the medical-device segment to accelerate once its acquisition of Synthes is fully integrated.

Though the firm lowered its full-year earnings-per-share outlook to $5.00-$5.07 from $5.07-$5.17, this updated outlook is mostly due to differences in currencies. Therefore, we feel the update is relatively immaterial to our estimate of the company’s intrinsic valuation. Johnson & Johnson scores a rare 9 on our Valuentum Buying Index, suggesting that the shares look very enticing at current levels. We also think the firm looks extremely attractive as a dividend growth investment, as there is an excellent chance the firm continues to increase its dividend many, many years into the future (and at a nice annual clip).


--------------------------------------------------
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor, and does not offer brokerage or investment banking services. The sources of the data used on this website and reports are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum, its employees, independent contractors and affiliates may have long, short or derivative positions in the securities mentioned on this website. The High Yield Dividend Newsletter portfolio, Best Ideas Newsletter portfolio and Dividend Growth Newsletter portfolio are not real money portfolios. Performance, including that in the Nelson Exclusive publication, is hypothetical and does not represent actual trading. Actual results may differ from simulated information, results, or performance being presented. For more information about Valuentum and the products and services it offers, please contact us at info@valuentum.com.